Luye Group 
Welcome,         Profile    Billing    Logout  
 36 Products   29 Diseases   36 Products   123 Trials   3033 News 


«12...56789101112131415...3334»
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Medicine
    Journal, IO biomarker:  Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer). (Pubmed Central) -  Aug 10, 2022   
    Tyrosine kinase inhibitors, antibody drug conjugate in monotherapy and combinations are emerging strategies in many HER2-positive cancers; HER2 therapies are now part of standard of care of HER2-amplified gastric or gastroesophageal junction cancer. Data are pending on several unmet medical needs.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Trial primary completion date, Real-world evidence, Real-world effectiveness, Real-world:  LURBICLIN: RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (clinicaltrials.gov) -  Aug 10, 2022   
    P=N/A,  N=200, Recruiting, 
    Data are pending on several unmet medical needs. Trial primary completion date: Jun 2022 --> Nov 2022
  • ||||||||||  Retrospective data, Review, Journal, IO biomarker, EGFR exon 20:  Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and pooled analysis of patient outcomes. (Pubmed Central) -  Aug 6, 2022   
    Conventional treatments used in patients with EGFR exon 20 insertion mutation-positive NSCLC have limited efficacy, though chemotherapy appeared to be associated with better response and survival outcomes than non-exon 20 targeting EGFR-TKIs and IO agents. This supports the need to identify EGFR exon 20 insertion mutations as the availability of new targeted treatments may offer additional therapeutic options to these patients.
  • ||||||||||  Lipusu (liposomal paclitaxel) / Luye Group
    Journal:  A facile method for anti-cancer drug encapsulation into polymersomes with a core-satellite structure. (Pubmed Central) -  Aug 6, 2022   
    Moreover, endocytic process of PTX@PS significantly inhibits drug transporter P-gp expression which could be largely activated by free drug diffusion. In glioma mice models, it has also confirmed that PTX@PS remarkably eradicate tumors, which renders polymersomes as a promising alternative to liposomes as drug carriers in clinic.
  • ||||||||||  Review, Journal:  A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC). (Pubmed Central) -  Aug 2, 2022   
    The preferred decades-old first line regimen was etoposide-platinum, to which ≥50% of patients respond, followed by decades-old, tired topotecan in second line for platinum sensitive patients, full stop, because there were no approved therapeutic options (nor generally any compelling experimental ones) in third line or beyond...A significant sea change occurred in 2018 with the approval of nivolumab followed by pembrolizumab and atezolizumab in 2019, durvalumab in 2020, accelerated approval for lurbinectedin in 2020 and trilaciclib in 2021 for myelosuppression...Suddenly, a tumor type, whose name was virtually synonymous with stalled progress and movement, and which was much less well studied and funded than its more prevalent cousin, non-small cell lung cancer (NSCLC), finds itself in the eye of the storm, that is, at the epicenter of an intense flurry and ferment of activity, not all of it positive. This review surveys approved drugs and select up-and-coming ones in development for extensive stage SCLC.
  • ||||||||||  poziotinib (HM 78136B) / Spectrum Pharma, Luye Group, Exkivity (mobocertinib) / Takeda, Gilotrif (afatinib) / Boehringer Ingelheim
    Clinical outcomes for EGFR/HER2 exon 20 insertion-mutated NSCLC (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_1867;    
    Table: 1110P Conclusions In this large, population-based retrospective review of EGFR and HER2 ex20ins NSCLC pts, there was improvement in survival for met pts who received any ST vs. those who did not. Among HER2 ex20 pts who received ST, overall survival was significantly better for those who received ex20ins-specific TKIs.
  • ||||||||||  poziotinib (HM 78136B) / Spectrum Pharma, Luye Group
    Journal, EGFR exon 20:  Location of EGFR exon 20 insertions matters. (Pubmed Central) -  Jul 15, 2022   
    In this issue of Cancer Cell, Elamin and colleagues demonstrate that only insertions localized in the near loop respond to poziotinib. Pharmacological inhibition of spindle assembly checkpoint components inhibits tumor growth in poziotinib-resistant exon 20 insertions.